Aaron G. Mammoser
Expertise in
23
conditions

Dr. Aaron G. Mammoser

Neurology | Neurosurgery
2001 Peachtree Road NE, Suite 645, 
Atlanta, GA 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Offers Telehealth
Referral may be required
Before you request
Expertise in
23
conditions
2001 Peachtree Road NE, Suite 645, 
Atlanta, GA 

Overview

Aaron Mammoser is a Neurologist and a Neurosurgery provider practicing medicine in Atlanta, Georgia.

Dr. Mammoser is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Glioma, Astrocytoma, Glioblastoma, and Brain Tumor.

Dr. Mammoser is board certified in American Board Of Psychiatry And Neurology. He is actively involved in clinical research, co-authoring 17 peer reviewed articles and participating in 10 clinical trials. Dr. Mammoser is currently accepting new patients.

Specialties

Neurology
Neurosurgery

Licenses

Psychiatry & Neurology in MI

Board Certifications

American Board Of Psychiatry And Neurology

Fellowships

University of Texas, MD Anderson Medical Center, Neuro-Oncology, 2011

Hospital Affiliations

Piedmont Newton Hospital
Piedmont Newnan Hospital, Inc
Piedmont Hospital, Inc
Piedmont Henry Hospital
Piedmont Fayette Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alliant Health
  • HMO
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Louisiana Healthcare Connections
  • HMO
  • MANAGED MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

Piedmont Physicians Neuro Oncology Atlanta
2001 Peachtree Road NE, Suite 645, Atlanta, GA 30309

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations
Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations
Enrollment Status: Recruiting
Publish Date: September 02, 2026
Intervention Type: Drug
Study Drugs: Vismodegib, GSK2256098, Capivasertib, Abemaciclib
Study Phase: Phase 2
GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM
GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM
Enrollment Status: Recruiting
Publish Date: July 30, 2026
Intervention Type: Drug, Radiation, Biological
Study Drugs: Temozolomide, Lomustine, Regorafenib, Paxalisib, VAL-083
Study Phase: Phase 2/Phase 3
Genomically-Guided Treatment Trial in Brain Metastases
Genomically-Guided Treatment Trial in Brain Metastases
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Drug
Study Drugs: Abemaciclib, Paxalisib, Entrectinib
Study Phase: Phase 2
A Single Arm, Pilot Study of Ramipril for Preventing Radiation-Induced Cognitive Decline in Glioblastoma (GBM) Patients Receiving Brain Radiotherapy
A Single Arm, Pilot Study of Ramipril for Preventing Radiation-Induced Cognitive Decline in Glioblastoma (GBM) Patients Receiving Brain Radiotherapy
Enrollment Status: Completed
Publish Date: March 13, 2026
Intervention Type: Drug
Study Drug: Ramipril
Study Phase: Phase 2
Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
Enrollment Status: Active_not_recruiting
Publish Date: January 22, 2026
Intervention Type: Drug, Radiation
Study Drugs: Concomitant Temozolomide (TMZ), Procarbazine, Adjuvant Temozolomide (TMZ), CCNU, Vincristine
Study Phase: Phase 3
Standard Chemotherapy Versus Chemotherapy Chosen by Cancer Stem Cell Chemosensitivity Testing in the Management of Patients With Recurrent Glioblastoma Multiforme (GBM).
Standard Chemotherapy Versus Chemotherapy Chosen by Cancer Stem Cell Chemosensitivity Testing in the Management of Patients With Recurrent Glioblastoma Multiforme (GBM).
Enrollment Status: Completed
Publish Date: April 15, 2025
Intervention Type: Diagnostic test, Drug
Study Phase: Phase 3
A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients With High Grade Glioma
A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients With High Grade Glioma
Enrollment Status: Completed
Publish Date: January 27, 2025
Intervention Type: Other, Drug
Study Phase: Phase 3
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Enrollment Status: Suspended
Publish Date: April 03, 2024
Intervention Type: Biological
Study Phase: Phase 3
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Enrollment Status: Terminated
Publish Date: February 07, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 2/Phase 3
A Phase 3, Randomized, Controlled, Double-Arm, Open-Label, Multi-center Study of VB-111 Combined With Bevacizumab vs. Bevacizumab Monotherapy in Patients With Recurrent Glioblastoma
A Phase 3, Randomized, Controlled, Double-Arm, Open-Label, Multi-center Study of VB-111 Combined With Bevacizumab vs. Bevacizumab Monotherapy in Patients With Recurrent Glioblastoma
Enrollment Status: Completed
Publish Date: October 23, 2018
Intervention Type: Drug
Study Phase: Phase 3
View 8 Less Clinical Trials

17 Total Publications

CRE25-043: Treatment of HER2-Positive Breast Cancer With Leptomeningeal Metastases With Intrathecal Trastuzumab.
CRE25-043: Treatment of HER2-Positive Breast Cancer With Leptomeningeal Metastases With Intrathecal Trastuzumab.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: March 28, 2025
Similar Doctors
Expertise in
22
conditions
Expertise in
22
conditions
Referral may be required
Before you request

Emory Clinic At 1365 Clifton Road

1365 Clifton Road Northeast, BldgB, 
Atlanta, GA 
 (3.5 miles away)
404-778-5770
Languages Spoken:
English, German, Korean, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Jonathan Grossberg is a Neurosurgery provider practicing medicine in Atlanta, Georgia. Dr. Grossberg is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Stroke, Brain Aneurysm, Subarachnoid Hemorrhage, Thrombectomy, and Stent Placement. Dr. Grossberg is board certified in American Board Of Neurological Surgery, 2013. Dr. Grossberg is currently accepting new patients.

Expertise in
19
conditions
Expertise in
19
conditions
Referral may be required
Before you request

Emory Brain Health Center

12 Executive Park Drive Northeast, 
Atlanta, GA 
 (4.1 miles away)
404-778-3444
Experience:
44+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Stewart Factor is a Neurologist practicing medicine in Atlanta, Georgia. He has been practicing medicine for over 44 years. Dr. Factor is highly rated in 19 conditions, according to our data. His clinical expertise encompasses Parkinson's Disease, Movement Disorders, Tardive Dyskinesia, Deep Brain Stimulation, and Thalamotomy. Dr. Factor is board certified in American Board Of Psychiatry And Neurology, 1989. Dr. Factor is currently accepting new patients.

Expertise in
15
conditions
Expertise in
15
conditions
Referral may be required
Before you request

Emory Brain Health Center

12 Executive Park Drive Northeast, 
Atlanta, GA 
 (4.1 miles away)
404-778-3444
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Hyder Jinnah is a Neurologist practicing medicine in Atlanta, Georgia. Dr. Jinnah is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Benign Essential Blepharospasm, Drug Induced Dyskinesia, Focal Dystonia, Torticollis, and Deep Brain Stimulation. Dr. Jinnah is board certified in American Board Of Psychiatry And Neurology, 1999. Dr. Jinnah is currently accepting new patients.

Frequently Asked Questions about Dr. Aaron G. Mammoser

How do I make an appointment with Dr. Aaron G. Mammoser?

You can book an appointment with Dr. Aaron G. Mammoser by calling their office at 404-605-2050. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Aaron G. Mammoser a top-rated expert for Glioma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Aaron G. Mammoser is classified as an Distinguished expert for Glioma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Aaron G. Mammoser specialize in?

While Dr. Aaron G. Mammoser is a Neurology, they have specific expertise in Glioma, Astrocytoma, and Glioblastoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Neurology.

Does Dr. Aaron G. Mammoser participate in research or clinical trials?

Yes. Dr. Aaron G. Mammoser has published 17 articles and abstracts on conditions like Glioma. You can view a list of Dr. Aaron G. Mammoser's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Aaron G. Mammoser accept my insurance?

Dr. Aaron G. Mammoser accepts most major insurance plans, including Aetna and Alliant Health. We recommend calling the office directly at 404-605-2050 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mammoser's expertise for a condition
ConditionClose
    View All 14 Distinguished Conditions
    View All 9 Advanced Conditions
    View All 35 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile